New drug combo shows promise for tough gynecological cancers

NCT ID NCT07448922

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called SKB518, given alone or with chemotherapy, in 280 people with advanced ovarian, cervical, or endometrial cancers. The goal is to see if the drug can shrink tumors or slow cancer growth. Researchers will also monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB518 (an experimental drug), carboplatin (chemotherapy), and bevacizumab (targeted therapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced gynecological cancers that are hard to treat.
What could go wrong: This is an early Phase 2 trial, so the drug may not work as hoped or could have unexpected side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial carcinoma female reproductive organ cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GYNECOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.